Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common
-
Shares outstanding
-
229M
-
Number of holders
-
99
-
Total 13F shares, excl. options
-
65.1M
-
Shares change
-
+540K
-
Total reported value, excl. options
-
$76.1M
-
Value change
-
+$642K
-
Put/Call ratio
-
0.09
-
Number of buys
-
46
-
Number of sells
-
-29
-
Price
-
$1.17
Significant Holders of Lineage Cell Therapeutics, Inc. - Common (LCTX) as of Q4 2022
110 filings reported holding LCTX - Lineage Cell Therapeutics, Inc. - Common as of Q4 2022.
Lineage Cell Therapeutics, Inc. - Common (LCTX) has 99 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 65.1M shares
of 229M outstanding shares and own 28.43% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (34.9M shares), VANGUARD GROUP INC (6.11M shares), Defender Capital, LLC. (5.09M shares), BlackRock Inc. (3.78M shares), Laurion Capital Management LP (2.38M shares), Prescott General Partners LLC (1.85M shares), RAFFLES ASSOCIATES LP (1.54M shares), GEODE CAPITAL MANAGEMENT, LLC (1.26M shares), JPMORGAN CHASE & CO (1.09M shares), and BRIDGEWAY CAPITAL MANAGEMENT, LLC (782K shares).
This table shows the top 99 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.